beclometasone-formoterol + salbutamol

This is a combination inhaled therapy consisting of beclometasone (an inhaled corticosteroid), formoterol (a rapid-onset, long-acting beta-2 adrenergic receptor agonist), and salbutamol (a short-acting beta-2 adrenergic receptor agonist). Beclometasone reduces airway inflammation, formoterol provides both rapid and sustained bronchodilation, and salbutamol offers quick relief of acute bronchospasm. This combination is used in the management of moderate to severe asthma, where maintenance therapy with beclometasone-formoterol is supplemented by as-needed use of salbutamol for symptom relief. The approach aims to optimize asthma control by addressing both chronic inflammation and acute bronchoconstriction[1][3][4].